As global markets navigate a complex landscape of inflationary pressures and geopolitical developments, Asian stock markets have shown resilience, with indices in Japan and China posting gains despite external challenges. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that align with favorable economic indicators and market dynamics.
Name
Current Price
Fair Value (Est)
Discount (Est)
SpiderPlus (TSE:4192)
¥502.00
¥994.80
49.5%
Shin Maint HoldingsLtd (TSE:6086)
¥1180.00
¥2323.25
49.2%
Shenzhen Envicool Technology (SZSE:002837)
CN¥31.63
CN¥62.34
49.3%
Lucky Harvest (SZSE:002965)
CN¥35.24
CN¥69.28
49.1%
Livero (TSE:9245)
¥1747.00
¥3431.97
49.1%
Hugel (KOSDAQ:A145020)
₩351500.00
₩699950.46
49.8%
HL Holdings (KOSE:A060980)
₩41300.00
₩81367.57
49.2%
HDC Hyundai Development (KOSE:A294870)
₩23300.00
₩45966.93
49.3%
Dive (TSE:151A)
¥955.00
¥1867.69
48.9%
cottaLTD (TSE:3359)
¥435.00
¥856.73
49.2%
Let’s explore several standout options from the results in the screener.
Overview: J&T Global Express Limited is an investment holding company providing integrated express delivery services across multiple countries including China, Indonesia, and Brazil, with a market cap of HK$86.12 billion.
Operations: The company’s revenue segments include Transportation – Air Freight, which generated $10.26 billion.
Estimated Discount To Fair Value: 31.9%
J&T Global Express appears undervalued based on cash flows, trading at HK$9.68, below its estimated fair value of HK$14.22. Despite a low forecasted return on equity of 18.1% in three years, the company shows robust growth potential with earnings expected to grow significantly at 32.7% annually and revenue outpacing the Hong Kong market at 11.1%. Recent results highlight operational strength with a substantial increase in parcel volume year-on-year.
SEHK:1519 Discounted Cash Flow as at Jul 2025
Overview: Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, manufactures, and sells skin treatment products featuring recombinant collagen in China, with a market cap of HK$61.82 billion.
Operations: The company’s revenue primarily comes from the research, development, manufacture, and sale of bioactive material-based beauty and health products, totaling CN¥5.54 billion.
Story Continues
Estimated Discount To Fair Value: 38.7%
Giant Biogene Holding is trading at HK$58.4, significantly below its estimated fair value of HK$95.21, suggesting undervaluation based on cash flows. Earnings are projected to grow 16.73% annually, outpacing the Hong Kong market’s 10.5%, with revenue growth expected at 18.1%. Despite high non-cash earnings, recent events include a follow-on equity offering of HK$2.33 billion and a special dividend announcement, reflecting strong shareholder returns amidst robust financial forecasts.
SEHK:2367 Discounted Cash Flow as at Jul 2025
Overview: Taiyo Yuden Co., Ltd. develops, manufactures, and sells electronic components across Japan, China, Hong Kong, and internationally with a market cap of ¥338.03 billion.
Operations: The company’s revenue is primarily derived from its Electronic Components Business, which generated ¥341.44 billion.
Estimated Discount To Fair Value: 45.3%
Taiyo Yuden is trading at ¥2710, below its estimated fair value of ¥4956.89, indicating potential undervaluation based on cash flows. Despite a volatile share price and lower profit margins compared to last year, earnings are forecast to grow significantly at 35% annually, outpacing the Japanese market’s growth rate. Recent product developments in automotive inductors and increased demand have positively impacted sales forecasts, although foreign exchange losses have tempered profit expectations.
TSE:6976 Discounted Cash Flow as at Jul 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1519 SEHK:2367 and TSE:6976.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com